RICHMOND, Calif., April 29, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics® will be presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Twelve oral and six poster presentations, given by Sangamo scientists and their academic collaborators, will detail data from Sangamo's therapeutic and research programs including HIV/AIDS, hemoglobinopathies, lysosomal storage disorders, and other monogenic diseases, cancer immunotherapy and advancements in technology including delivery. Additionally, members of Sangamo's management team and Company scientists will participate in the C-Suite Executive Panel and two Education Sessions. The meeting will be held in New Orleans, LA, from May 13-16, 2015.
"Our ZFP Therapeutic platform features prominently at this year's ASGCT Annual Meeting, the premier forum for the field of gene and cell therapy, with Sangamo-authored presentations selected for the Presidential Symposium as well as the Clinical Trials Spotlight," said Edward Lanphier, Sangamo's president and CEO. "Data will be presented from our clinical and preclinical studies demonstrating the specificity, versatility and maturity of Sangamo's powerful ZFN genome editing platform across a wide range of therapeutic applications."
The following presentations are scheduled at the ASGCT Meeting sessions:
HIV/AIDS
- Adoptive Transfer of ZFN Mediated CCR5 Modified CD4 T-cells (SB-728-T) in HIV Subjects Leads to Long Term Engraftment of HIV Resistant T Memory Stem Cells and Decrease in Size of Latent Reservoir Abstract #C-7
Session:Clinical Trials Spotlight
Oral Presentation Thursday, May 14, 2015 - A Dose Escalation Study of Cyclophosphamide (CTX) to Enhance SB-728-T Engraftment Abstract #25
Session:Hematologic and Immunologic Diseases: Clinical Trials and Observations
Oral Presentation Wednesday, May 13, 2015 - Long-Term, Multilineage Engraftment of Zinc Finger Nuclease-Edited Hematopoietic Stem Cells in Nonhuman Primates Abstract #684
Session: Gene Editing and Gene Regulation III
Oral Presentation Saturday, May 16, 2015 - Helper-Dependent Ad5/35 Vectors for ZFN Mediated Gene Editing in Hematopoietic Stem Cells Abstract #123
Session: Gene Targeting and Gene Correction I
Poster Session Wednesday, May 13, 2015
Hemoglobinopathies
- From GWAS to the Clinic: Genome-Editing the Human Bcl11a Erythroid Enhancer for Fetal Globin Elevation in the Hemoglobinopathies Abstract #53
Session:Gene Editing and Gene Regulation I
Oral Presentation Wednesday, May 13, 2015 - Preclinical Studies for the First Hematopoietic Stem Cell (Hsc) Gene Editing Trial: Phase 1 Study of Beta-Thalassemia with Autologous Transplantation of Zinc Finger Nuclease-Treated Hsc to Upregulate Fetal Hemoglobin Abstract #239
Session:Hematologic and Immunologic Diseases I
Poster Session Wednesday, May 13, 2015 - Correction of the Sickle-Cell Disease Mutation in Human Hematopoietic Stem/Progenitor Cells Abstract #115
Session: Gene Targeting and Gene Correction I
Poster Session Wednesday, May 13, 2015
Lysosomal Storage Disorders
- ZFN-Mediated In Vivo Genome Editing Results in Supraphysiological Levels of Lysosomal Enzymes Deficient in Hunter and Hurler Syndrome and Gaucher Disease Abstract #479
Session: Gene Editing and Gene Regulation II
Oral Presentation Friday, May 15, 2015
Cancer Immunotherapy
- Clinical Scale Zinc Finger Nuclease (ZFN)-Driven Gene-Editing of PD-1 in Tumor Infiltrating Lymphocytes (TIL) for the Potential Treatment of Metastatic Melanoma Abstract #77
Session:Cell Manufacturing, Vector Production, and Biodistribution for Clinical Translation
Oral Presentation Wednesday, May 13, 2015 - TCR Gene Editing in a Single Step of T Cell Activation to Redirect T Cell Specificity and Prevent GvHD Abstract #209
Session: Cancer Immunotherapy, Cancer Vaccines I
Poster Session Wednesday, May 13, 2015
Monogenic Diseases
- Genome Editing of Primary Human CD34+ Hematopoietic Stem Cells Enables a Safe Harbor Targeted Gene Addition Therapeutic Strategy for Chronic Granulomatous Disease Abstract #54
Session:Gene Editing and Gene Regulation I
Oral Presentation Wednesday, May 13, 2015 - Targeted Genome Editing in Mouse Hematopoietic Stem/Progenitor Cells (HSPC) to Model Gene Correction of SCID-X1 Abstract #481
Session: Gene Editing and Gene Regulation II
Oral Presentation Friday, May 15, 2015 - Gene Correction of IL2RG in Human Hematopoietic Stem and Progenitor Cells Abstract #686
Session: Gene Editing and Gene Regulation III
Oral Presentation Saturday, May 16, 2015 - Targeted Correction and Restored Function of CFTR Gene in Cystic Fibrosis Induced Pluripotent Stem Cells Abstract #185
Session: Cardiovascular and Pulmonary Diseases
Poster Session Wednesday, May 13, 2015 - Gene Edition for Wiskott-Aldrich Syndrome Gene Therapy Abstract #342
Session: Gene Targeting and Gene Correction II
Poster Session Thursday, May 14, 2015
Technology Developments and other Applications
- Highly Efficient Targeted Gene Addition in CD34+ Hematopoietic Stem/Progenitor Cells by Combining ZFN mRNA and AAV6 Donor Delivery Abstract #478
Session:Presidential Symposium
Oral Presentation Friday, May 15, 2015 - AAVHSC Vectors Encoding Zinc-Finger Nucleases Mediate Efficient Targeted Integration at the Human AAVS1 Locus in CD34+ Human Hematopoietic Stem Cells Abstract #55
Session: Gene Editing and Gene Regulation I
Oral Presentation Wednesday, May 13, 2015 - Targeted Genome Editing of Cell Lines for Improved and Scalable Production of Lentiviral Vectors for Human Gene Therapy Abstract #6
Session: RNA Virus Vectors
Oral Presentation Wednesday, May 13, 2015
Panel and Discussion Sessions
- Messaging and other strategic tools for successful commercialization in a landscape where zero to few approved therapeutic products exist Panelist: Edward Lanphier, President and CEO
Session: C-Suite Executive Panel
Panel Discussion Tuesday, May 12, 2015 - Therapeutic Gene Editing A Biotech Perspective Speaker: Philip D. Gregory, D.Phil., Senior Vice President, Research and CSO
Session: Education Session 400: Emerging Field Review: Gene Editing
Discussion Session Saturday, May 16, 2015 - Science Funding Challenges: Perspectives from Biopolicy, Bioeconomics and Bioethics Session Co-Chair: Thomas Wechsler, Ph.D., Scientist III
Session: Education Session 135: Topical Review
Discussion Session Wednesday, May 13, 2015
All abstracts for the ASGCT meeting are available online at 2015 ASGCT Annual Meeting Abstracts.
About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic CuresTM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has clinical stage programs to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728) and beta-thalassemia (SB-BCLmR-HSPC). Sangamo's other therapeutic programs are focused on monogenic and rare diseases. The Company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sangamo-biosciences-and-collaborators-to-present-data-on-zfp-therapeutic-applications-at-annual-meeting-of-the-american-society-of-gene-and-cell-therapy-300073814.html
SOURCE Sangamo BioSciences, Inc.
Help employers find you! Check out all the jobs and post your resume.
